News Archive

2019

May

Media Release / May 24, 2019

AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)

Read More
Media Release / May 16, 2019

Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders

Read More
Media Release / May 16, 2019

Five nonprofit organizations to receive up to $250,000 through Novartis STEP Program™ to support sickle cell patient initiatives

Read More
Media Release / May 11, 2019

Novartis issues voluntary nationwide recall of Promacta® 12.5 mg for oral suspension due to potential peanut contamination

Read More
Media Release / May 07, 2019

New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1

Read More
Media Release / May 05, 2019

AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients

Read More

April

Media Release / Apr 15, 2019

Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD

Read More
Media Release / Apr 01, 2019

AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado

Read More

March

Media Release / Mar 27, 2019

Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease

Read More
Media Release / Mar 16, 2019

Novartis late-breaking data further support initiation of Entresto in hospital and as a first-choice systolic heart failure therapy in stabilized patients

Read More

Related Links